LA JOLLA, Calif., Jan. 27, 2021 /PRNewswire/ -- Regulus
Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company
focused on the discovery and development of innovative medicines
targeting microRNAs, today announced Alice
S. Huang, Ph.D. has been appointed to the Company's board of
directors. Concurrently with her appointment to the Board, Dr.
Huang was appointed to serve on the Compensation Committee.
"We are pleased to add Dr. Huang to the Regulus board. We
believe her extensive scientific background will be of benefit to
helping direct the Company's drug discovery and development
programs," said Stelios
Papadopoulos, Ph.D., Chairman of the Board of Directors of
Regulus.
Dr. Huang is currently Senior Faculty Associate of Biology and
Biological Engineering at the California
Institute of Technology having joined Caltech in July
1997. Previous to her tenure at Caltech she was Dean for
Science and Professor of Biology at New York
University, Professor of Microbiology and Molecular Genetics
at Harvard Medical School and Director,
Laboratories of Infectious Disease at Boston Children's
Hospital. She also served as director of Virus-Host
Interactions in Cancer for 15 years, a training program
at Harvard funded by the National
Cancer Institute. Dr. Huang has served on the Board of
Trustees of the Keck Graduate Institute
since 1998 and has previously served on the Board of Trustees of
Waksman Foundation for Microbiology, the Rockefeller Foundation,
Public Agenda, Johns Hopkins
University, the Health Effects Institute, and the
University of Massachusetts. Dr. Huang
is serving on the advisory boards of the Institute for Basic
Biomedical Sciences at Johns Hopkins
University School of Medicine since 2008 as well as the
Schlesinger Library at Radcliffe Institute since 2018. She has
previously served on the advisory boards of the National Foundation
for Infectious Diseases, the US Army Medical Research &
Development Command and Food & Drug Administration. She
has been a fellow of the American Association of Women in Science
since 1978, American Academy of Microbiology since 1982, Academia
Sinica in Taiwan since
July 1990, and the American
Association for the Advancement of Science since 2000, serving as
its president from 2010 to 2011.
Dr. Huang received her B.A., M.A. and Ph.D. degrees from the
Johns Hopkins University.
About Regulus
Regulus Therapeutics Inc. (Nasdaq: RGLS) is a biopharmaceutical
company focused on the discovery and development of innovative
medicines targeting microRNAs. Regulus maintains its
corporate headquarters in La
Jolla, CA.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/regulus-announces-addition-to-board-of-directors-301216007.html
SOURCE Regulus Therapeutics Inc.